This is a profile image of Lucy Pérez

Lucy Pérez

Senior PartnerBoston

Advises pharmaceutical, biotech, and medical product companies and healthcare providers as they address strategic, organizational, and operational challenges


A former cancer researcher, Lucy brings a strong technical background to her work with organizations across the life-sciences sector. Since joining McKinsey, she has partnered with CEOs and top teams at leading organizations across North America, Europe, and Asia. She leads our evidence-generation work within the Life Sciences Practice, helping clients generate and apply research insights, clinical data, and real-world evidence to maximize patient benefit, demonstrate product value, and catalyze innovation.

Whether working with established pharmaceutical companies to hone R&D investments and optimize commercial operations or advising healthcare providers on growth and innovation, Lucy takes a strategic, long-term perspective. Given her background in oncology, she often works with clients in the optimization of asset development and commercialization plans as well as improving specialized-care delivery approaches.

Examples of her recent client work include the following:

  • advising a biopharmaceutical company setting clinical, regulatory, and medical strategies for a suite of treatments for infectious diseases and oncology
  • supporting a leading pharmaceutical company through digital transformation to transform how it engages with customers, applies advanced analytics, and embeds agile ways of working
  • assessing internal and external portfolio-productivity and pricing models to optimize the R&D strategy and redesign the organization for a top pharmaceutical company
  • developing a corporate growth strategy for a top US cancer center
  • designing an operating model for a new innovation center at a major academic medical center to boost the translation of biomedical research into clinical-care solutions
  • designing a US regional commercial model for the field force of a leading pharmaceutical company to better respond to the needs of integrated health systems

In addition to her client service, Lucy coleads our North America Hispanic Latino Network, a platform for consultants and Hispanic and Latino leaders to connect and build community as well as advance their professional development.

Lucy also supports life-sciences clients with the development and implementation of sustainable operations and their strategy for environmental, social, and sustainability governance.

Before joining McKinsey, Lucy was a research fellow at Memorial Sloan Kettering Cancer Center, where she was involved in the development of novel treatments for solid tumors. She was also a Howard Hughes Medical Institute research fellow at Harvard University while completing her doctoral studies. She is the coinventor on multiple patents and has published in peer-reviewed journals.

Published work

The economic state of Latinos in the US: Determined to thrive,” McKinsey & Company, November 2022

How to make ESG real,” McKinsey & Company, August 2022

Does ESG really matter—and why?,” McKinsey & Company, August 2022

Digital health: An opportunity to advance health equity,” McKinsey & Company, July 2022

Self-learning: The dawn of a new biomedical R&D paradigm,” McKinsey & Company, July 2022

What will it take to boost Latino economic power?,” McKinsey & Company, May 2022

Better data for better therapies: The case for building health data platforms,” McKinsey & Company, April 2022

Health equity: A framework for the epidemiology of care,” McKinsey & Company, March 2022

The dawn of the FemTech revolution,” McKinsey & Company, February 2022

Unlocking opportunities in women’s healthcare,” McKinsey & Company, February 2022

The economic state of Latinos in America: The American dream deferred, McKinsey & Company, December 2021

Integrated evidence generation: A paradigm shift in biopharma,” McKinsey & Company, November 2021

US Hispanic and Latino lives and livelihoods in the recovery from COVID-19,” McKinsey & Company, September 2020

Creating value from next-generation real-world evidence,” McKinsey & Company, July 2020


Harvard University
PhD, chemistry
AB, chemistry